Admune Therapeutics: Novartis broadens immunooncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

Novartis International AG Novartis broadens immunooncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible f...